# Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy

## TL;DR

The paper introduces a new framework to better understand why some people don't respond well to GLP-1 receptor agonist treatments.

## Contribution

A novel mechanistic framework is proposed to reclassify incretin resistance into three subtypes for improved therapeutic strategies.

## Key findings

- Three mechanistic subtypes of incretin resistance are defined: receptor-level, post-receptor, and secretory.
- The framework allows for more personalized treatment approaches beyond the 'non-responder' label.

## Abstract

This article introduces a mechanistic framework to reclassify suboptimal responses to GLP-1 receptor agonists. It defines three mechanistic subtypes of incretin resistance—receptor-level, post-receptor, and secretory—highlighting their distinct pathways and therapeutic implications. This model promotes personalized care by moving beyond the oversimplified ‘non-responder’ classification.